Get started
Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AMLX chart


Full chart

Key facts today

Amylyx Pharmaceuticals, Inc. will report its Q3 2024 financial results on November 7, 2024, followed by a conference call at 8:00 a.m. ET to discuss the results and company updates.
Analyze the impactAnalyze the impact

AMLX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪383.99 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.44USD
Net income (FY)
‪49.27 M‬USD
Revenue (FY)
‪380.79 M‬USD
Shares float
‪41.21 M‬
Beta (1Y)
1.43

Employees


Employees (FY)
384
Change (1Y)
+122 +46.56%
Revenue / Employee (1Y)
‪991.63 K‬USD
Net income / Employee (1Y)
‪128.31 K‬USD

About Amylyx Pharmaceuticals, Inc.


Sector
Health Technology
Headquarters
Cambridge
Founded
2013
Website
amylyx.com
FIGI
BBG00DP10YT5
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

AMLX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AMLX is 5.70 USD — it has increased by 1.06% in the past 24 hours. Watch Amylyx Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Amylyx Pharmaceuticals, Inc. stocks are traded under the ticker AMLX.
AMLX stock has risen by 6.94% compared to the previous week, the month change is a 93.88% rise, over the last year Amylyx Pharmaceuticals, Inc. has showed a −69.11% decrease.
We've gathered analysts' opinions on Amylyx Pharmaceuticals, Inc. future price: according to them, AMLX price has a max estimate of 10.00 USD and a min estimate of 3.00 USD. Watch AMLX chart and read a more detailed Amylyx Pharmaceuticals, Inc. stock forecast: see what analysts think of Amylyx Pharmaceuticals, Inc. and suggest that you do with its stocks.
AMLX reached its all-time high on Jan 30, 2023 with the price of 41.93 USD, and its all-time low was 1.58 USD and was reached on Jun 17, 2024. View more price dynamics on AMLX chart.
See other stocks reaching their highest and lowest prices.
AMLX stock is 5.36% volatile and has beta coefficient of 1.43. Track Amylyx Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Amylyx Pharmaceuticals, Inc. there?
Today Amylyx Pharmaceuticals, Inc. has the market capitalization of ‪383.99 M‬, it has increased by 7.55% over the last week.
Yes, you can track Amylyx Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Amylyx Pharmaceuticals, Inc. is going to release the next earnings report on Nov 7, 2024. Keep track of upcoming events with our Earnings Calendar.
AMLX earnings for the last quarter are −1.07 USD per share, whereas the estimation was −0.73 USD resulting in a −46.58% surprise. The estimated earnings for the next quarter are −0.70 USD per share. See more details about Amylyx Pharmaceuticals, Inc. earnings.
Amylyx Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪−1.02 M‬ USD, despite the estimated figure of ‪10.66 M‬ USD. In the next quarter, revenue is expected to reach 0.00 USD.
AMLX net income for the last quarter is ‪−72.70 M‬ USD, while the quarter before that showed ‪−118.79 M‬ USD of net income which accounts for 38.80% change. Track more Amylyx Pharmaceuticals, Inc. financial stats to get the full picture.
No, AMLX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 384.00 employees. See our rating of the largest employees — is Amylyx Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Amylyx Pharmaceuticals, Inc. EBITDA is ‪−153.78 M‬ USD, and current EBITDA margin is 10.48%. See more stats in Amylyx Pharmaceuticals, Inc. financial statements.
Like other stocks, AMLX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Amylyx Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Amylyx Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Amylyx Pharmaceuticals, Inc. stock shows the sell signal. See more of Amylyx Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.